A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED)

A Randomized, Double-Blinded, Tolerability and Immunogenicity Study of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered Concomitantly With GARDASIL to 16- to 26- Year-Old Women

The purpose of this study is to evaluate vaccine immunogenicity and how well the body tolerates V504 when given with Gardasil.

Inclusion Criteria:

• Females between 16- to 26-years-old
• Has never had Pap testing or has only had normal Pap test results.
• Lifetime history of 0 to 4 sexual partners

Exclusion Criteria:

• History of an abnormal cervical biopsy result
• History of a positive test for HPV; History of external genital/vaginal warts
• Currently a user of illegal drugs or an alcohol abuser
• History of severe allergic reaction that required medical attention
• Are pregnant
• Received a marketed HPV vaccine
• Currently enrolled in a clinical trial
• Currently has or has a history of certain medical conditions or is currently taking or has taken certain medications (details will be discussed at the time of consent)